Navigation Links
Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings

ALISO VIEJO, Calif., Aug. 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States. A link to the online article can be accessed at


PRISM investigators enrolled 5290 patients with six common neurologic conditions often associated with PBA. More than one third of enrolled patients (n = 1944; 36.7%) had a CNS-LS score ≥13, suggesting PBA symptoms. The impact of the patient's neurological condition on quality of life (QOL) was significantly higher (worse) in these patients (mean score 6.7 vs. 4.7; P<0.0001). In addition, a greater percentage of patients with CNS-LS score ≥13 were being treated with antidepressant/antipsychotic medications (53.0% vs. 35.4%, respectively; P<0.0001). 

"The results from PRISM demonstrate that PBA symptoms are common among patients with diverse neurological conditions," said Randall Kaye, MD, chief medical officer at Avanir Pharmaceuticals. "Higher CNS-LS scores were associated with significantly worse quality of life scores and greater use of antipsychotic/antidepressant medications. Publication of this important information will help healthcare practitioners better appreciate the frequency and multi-faceted impact of PBA symptoms in their neurologic patients."

The PBA Registry Series (PRISM) was established to provide PBA symptom prevalence data in a large, representative U.S. sample of patients in a clinical setting with neurological conditions known to be associated with PBA. A total of 5,290 patients were enrolled across 173 study sites, including 1,799 (34.0%) patients with Alzheimer's disease; 125 (2.4%) with amyotrophic lateral sclerosis (Lou Gehrig's disease), 1,215 (23.0%) with multiple sclerosis, 804 (15.2%) with Parkinson's disease, 757 (14.3%) with stroke, and 590 (11.2%) with traumatic brain injury.

About PBA
PBA is a neurologic condition characterized by emotional outbursts that are often contrary or exaggerated to the patient's inner mood state, causing them to laugh or cry uncontrollably. As a result, many of those afflicted with PBA show significant impairment on standard measures of health status, and disruption in occupational and social function, often leading to social isolation. PBA occurs secondary to a variety of neurologic conditions such as traumatic brain injury (TBI), multiple sclerosis (MS), Lou Gehrig's disease (ALS), Parkinson's disease, stroke and Alzheimer's disease. When these disorders damage areas of the brain that regulate normal emotional expression, they can lead to uncontrollable, disruptive episodes of crying or laughing. For more information about PBA, please visit

The CNS-LS has been validated in ALS and MS patients.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
+1 (949) 389-6700

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
2. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
3. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
4. Avanir Pharmaceuticals to Participate in Two Conferences in August
5. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
7. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
8. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
9. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
10. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Trovagene, Inc. ... diagnostics, today announced that Chief Executive Officer Antonius Schuh, ... the 27 th Annual Piper Jaffray Healthcare Conference. ... at the New York Palace Hotel in ... at 1:30 p.m. EST. Mr. Schuh will be available ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... their Black Friday sale a week early, offering 40% off select bras and ... intimate apparel industry through both mobile fit technology and the latest fashion, quickly ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), the ... Company as its newest Partner Firm. Based in Jefferson City, Missouri, their core ... advisor regardless of whether that client is a business, a family, or an ...
(Date:11/24/2015)... LINCOLN, R.I. (PRWEB) , ... November 24, 2015 , ... ... why Amica Insurance is sharing safety tips to help protect your family and vehicle. ... traffic crashes around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety ...
Breaking Medicine News(10 mins):